Penultimate observation carried forward (POCF): A new approach to analysis of long-term symptom change in chronic relapsing conditions [1]

Schizophrenia Research

Volumn 60, Issue 2-3, 2003, Pages 319-320

  O'Connor, Rory ^a   Schooler, Nina R ^b  

^a PFIZER INC   (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; ZIPRASIDONE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; HUMAN; LETTER; LONG TERM CARE; OBSERVATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCHIZOPHRENIA; SYMPTOM; SYMPTOMATOLOGY;

EID: 0037395113     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(02)00309-2     Document Type: Letter

References (4)

1. Arató M., O'Connor R., Bradbury J.E., Meltzer H. Ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia. Eur. Psychiatry. 13(4):1998;303.
2. DeQuardo J.R., Tandon R. Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia? J. Psychiatr. Res. 32:1998;229-242.
3. Schooler N.R. Maintenance medication for schizophrenia: strategies for dose reduction. Schizophr. Bull. 17:1991;311-324.
4. Viguera A.C., Baldessarini R.J., Hegarty J.D., van Kammen D.P., Tohen M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch. Gen. Psychiatry. 54(1):1997;49-55.